Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay JP, Smith R, Devlin K, Hollern DP, Liby T, Liu M, Boddapati S, Watson SS, Esch A, Zheng T, Thompson W, Babcock D, Kwon S, Chin K, Heiser L, Gray JW, Korkola JE.
Garay JP, et al. Among authors: babcock d.
Breast Cancer Res. 2021 Aug 3;23(1):81. doi: 10.1186/s13058-021-01457-0.
Breast Cancer Res. 2021.
PMID: 34344439
Free PMC article.